PF-00299804 As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Complete the Trial Form Below:
You may be eligible for this study if you meet the following criteria:
Conditions: Carcinoma, Non-small Cell
Age: Between 18 - 100 Years
Gender: Male or Female
This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (<100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years) or have known EGFR activating mutation; or patients with HER 2 amplification or mutation.